Dupilumab Versus Cyclosporine for the Treatment of Moderate-to-Severe Atopic Dermatitis in Adults: Indirect Comparison Using the Eczema Area and Severity Index

• Main Authors: Lieneke F.M. Ariëns (Author), Abhijit Gadkari (Author), Harmieke van Os-Medendorp (Author), Rajeev Ayyagari (Author), Emi Terasawa (Author), Andreas Kuznik (Author), Zhen Chen (Author), Gaëlle Bégo-Le Bagousse (Author), Yufang Lu (Author), Elena Rizova (Author), Neil M.H. Graham (Author), Gianluca Pirozzi (Author), Marjolein De Bruin-Weller (Author), Laurent Eckert (Author)
• Format: Book
• Published: Medical Journals Sweden, 2019-06-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Dupilumab is approved for uncontrolled moderate-to-severe atopic dermatitis (AD); cyclosporine is approved for severe AD for <1 year. The efficacy/effectiveness of these treat­ments was compared indirectly. Regression models used pooled patient-level data to estimate response (Eczema Area and Sev...